The Ministry of Health, through the Pharmacy and Poisons Board (PPB), has issued a recall notice for Tamedol oral solution (Paracetamol oral solution, 120mg/5m1, 60 mls) due to concerns about its safety and effectiveness. This decision comes in response to complaints received regarding the drug’s performance.

The PPB, in an official statement, announced that the Tamedol oral solution, produced by Biopharma LTD, did not meet the required market authorization standards. Consequently, the board has advised all pharmaceutical outlets, healthcare facilities, healthcare professionals, and the general public to immediately cease the distribution and use of this specific medication.

The statement instructs, “STOP all further distribution, sale, issuing, or use of Tamedol oral solution. Members of the public should return the product to their nearest healthcare facility, while healthcare facilities are directed to return the products to their respective suppliers.”

Additionally, the PPB expressed concerns about the sale of Visipaque (Iodixanol) 320 mg/mL vial due to reports of quality issues and suspected adverse events. Preliminary investigations revealed that these affected product batches had entered the market through unauthorized and illegal supply chains, raising serious safety concerns.